ACTRN12620000731998尚未招募1 期
Safety and efficacy of a pharmacological strategy using Losartan in hospital patients with COVID-19
SW Health via the Hunter New England Local Health District0 个研究点目标入组 36 人开始时间: 2020年7月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Confirmed SARS-CoV-2 infection by any method
- •Current admission as inpatient to hospital ward for management of COVID-19
排除标准
- •Current use of RAS agent
- •Known contra-indication to any RAS agent
- •Participation in another clinical trial for COVID-19 or SARS-CoV-2
- •Current or previous admission to ICU for COVID-19 management
研究者
相似试验
尚未招募
3 期
Safety and Efficacy of Rifampicine 600 mg, Moxifloxacine 400mg and Minocycline 100 mg for leprosy patients: An open ended randomized trialCTRI/2019/02/017812Indian Council of Medical Research
招募中
2 期
Efficacy and safety study of a therapeutic regimen using Tamibarotene (Am80) and arsenic trioxide (ATO) in combination with Gemtuzumab Ozogamicin (GO) as a post-remission therapy for relapsed acute promyelocytic leukemia (APL)Relapsed acute promyelocytic leukemiaRelapsed acure promyelocytic leukemia, Tamibarotene, Arsenic trioxide, Gemtuzumab ozogamicinJPRN-jRCTs041190101Kiguchi Toru39
进行中（未招募）
1 期
Evaluation the safety and efficacy of the treatment of scars and cutis laxa syndrome with the use of autologous (fresh and stored) stem cells isolated from adipose tissue within the project: 'The therapeutic potential of mesenchymal stem cells tested in clinical trials and in vitro - a justification for characterized cells storage'.EUCTR2016-004110-10-PLMedical University of Warsaw100
进行中（未招募）
1 期
A fibrinogen concentrate study in paediatric patients with inherited fibrinogen deficiencyAfibrinogenaemia or severe hypofibrinogenaemiaMedDRA version: 16.1Level: LLTClassification code 10052651Term: AfibrinogenaemiaSystem Organ Class: 100000004850MedDRA version: 16.1Level: PTClassification code 10051125Term: HypofibrinogenaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-000261-36-FRFB Biotechnologies16
进行中（未招募）
不适用
A fibrinogen concentrate study in paediatric patients with inherited fibrinogen deficiencyAfibrinogenaemia or severe hypofibrinogenaemiaMedDRA version: 16.1Level: LLTClassification code 10052651Term: AfibrinogenaemiaSystem Organ Class: 100000004850MedDRA version: 16.1Level: PTClassification code 10051125Term: HypofibrinogenaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-000261-36-Outside-EU/EEAFB Biotechnologies12